Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) had its price objective cut by research analysts at Piper Sandler from $12.00 to $8.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price target would suggest a potential upside of 175.86% from the stock’s current price.
Other analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Alpha Tau Medical in a research report on Wednesday, September 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $23.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, August 29th.
Alpha Tau Medical Stock Down 1.0 %
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last posted its quarterly earnings results on Monday, August 28th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). Equities research analysts expect that Alpha Tau Medical will post -0.49 EPS for the current fiscal year.
Institutional Trading of Alpha Tau Medical
A number of large investors have recently made changes to their positions in the stock. Penserra Capital Management LLC bought a new stake in Alpha Tau Medical in the 1st quarter worth approximately $40,000. Activest Wealth Management bought a new stake in shares of Alpha Tau Medical in the second quarter worth $28,000. Tower Research Capital LLC TRC purchased a new stake in Alpha Tau Medical during the third quarter valued at $37,000. Geode Capital Management LLC lifted its holdings in Alpha Tau Medical by 31.4% in the first quarter. Geode Capital Management LLC now owns 26,606 shares of the company’s stock valued at $76,000 after acquiring an additional 6,364 shares during the period. Finally, Morgan Stanley boosted its position in Alpha Tau Medical by 60.6% in the fourth quarter. Morgan Stanley now owns 18,603 shares of the company’s stock worth $59,000 after purchasing an additional 7,020 shares during the last quarter. 1.47% of the stock is currently owned by institutional investors.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
- Five stocks we like better than Alpha Tau Medical
- Find and Profitably Trade Stocks at 52-Week Lows
- Unity Software’s resilient rebound post-earnings setback
- Stock Splits, Do They Really Impact Investors?
- 3 ETFs that offer extreme diversification
- How to Calculate Stock Profit
- Williams-Sonoma is a steal for buy-and-hold investors
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.